Elestrin (estradiol gel) 0.06% is provided by Meda Pharmaceuticals Inc., headquartered in Somerset, New Jersey. We invite your comments and questions about Elestrin or any information you see on our website. You can contact Meda Pharmaceuticals about Elestrin at:
Warning: Endometrial cancer, cardiovascular disorders, breast cancer and probable dementia
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT)
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
Estrogen Plus Progestin Therapy
Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
The WHI estrogen plus progestin substudy reported increased risk of stroke, DVT, pulmonary embolism (PE), and myocardial infarction (MI)
The WHI estrogen plus progestin study reported increased risks of invasive breast cancer
The WHIMS estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older
ELESTRIN should not be used in women with any of the following conditions:
Undiagnosed abnormal genital bleeding
Known, suspected, or history of breast cancer
Known or suspected estrogen-dependent neoplasia
Active DVT, PE, or history of these conditions
Active arterial thromboembolic disease (for example, stroke and MI) or a history of these conditions
Known anaphylactic reaction or angioedema to ELESTRIN
Known liver impairment or disease
Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
Known or suspected pregnancy
Estrogens increase the risk of gallbladder disease.
Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia or choloestatic jaundice occurs.
Monitor thyroid function in women on thyroid replacement therapy.
In a placebo-controlled trial that included a total of 484 postmenopausal women, the most common adverse reactions (≥ 5 percent) are breast tenderness, metrorrhagia, nasopharyngitis, and upper respiratory tract infections.
Inducers and/or inhibitors of CYP3A4 may effect estrogen drug metabolism.
ELESTRIN (estradiol gel) is used for the treatment of moderate to severe vasomotor symptoms due to menopause.
You are encouraged to report suspected adverse reactions. To report SUSPECTED ADVERSE REACTIONS, contact Mylan Pharmaceuticals Inc. at 1-877-446-3679 (1-877-4-INFO-RX) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.